Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232527CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IMMUNOGENIC COMPOSITIONS
WO 26.11.2020
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/CA2019/051592 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
The present disclosure relates to DNA vaccines against Crimean-Congo Hemorrhagic Fever (CCHF) virus. The present disclosure also relates to CCHF virus sequences and their use for vaccination such as DNA vaccination. The present disclosure more particularly relates to artificial nucleic acid molecules that are able to encode a CCHF polypeptide of an infectious CCHF virus, a fragment or a variant thereof. The nucleic acid molecules of the present application are formulated as immunogenic compositions.
2.WO/2020/234387IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
WO 26.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/EP2020/064132 Applicant CYTUNE PHARMA Inventor MOEBIUS, Ulrich
The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor βɣ (IL-2/IL-15Rβɣ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15Rβɣ agonists on 2, 3 or 4 consecutive days followed by days without administration.
3.WO/2020/234547NOVEL BACTERIOPHAGE STRAINS AND USES THEREOF
WO 26.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/FR2020/050848 Applicant VETOPHAGE Inventor CHATAIN-LY, Mai Huong
The present invention relates to a composition comprising a bacteriophage strain or a mixture of bacteriophage strains selected from strains such as those stored at the CNCM under numbers CNCM I-5409, CNCM I-5410, CNCM I-5491 and CNCM I-5492. The invention also relates to the therapeutic use of said strains in humans and animals to treat S. aureus infections, in particular for treating mastitis in animals.
4.WO/2020/235567FLUORESCENT PROBE FOR USE IN DETECTION OF BRAIN TUMOR
WO 26.11.2020
Int.Class C07K 5/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
Appl.No PCT/JP2020/019814 Applicant THE UNIVERSITY OF TOKYO Inventor KITAGAWA Yosuke
[Problem] To provide a novel fluorescent probe which can be used in a spray mode, has excellent specificity to sensitivity, also has immediacy, and enables the detection of brain tumor. [Solution] A fluorescent probe for use in the detection of brain tumor, which comprises a compound represented by formula (I) or a salt thereof: (in the formula, P1 represents an arginine residue, a histidine residue or a tyrosine residue, and P2 represents a proline residue or a glycine residue, wherein P1 is liked to an adjacent N atom to form an amide bond, and P2 is linked to P1 to form an amide bond; R1 represents 1 to 4 same or different substituents independently selected from the group consisting of a hydrogen atom and an alkyl group, a carboxyl group, an ester group, an alkoxy group, an amide group and an azide group each of which may be substituted; R2, R3, R4, R5, R6 and R7 independently represent a hydrogen atom, a hydroxyl group, an alkyl group which may be substituted, or a halogen atom; R8 and R9 independently represent a hydrogen atom or an alkyl group; X represents O, Si(Ra)(Rb), Ge(Ra)(Rb), Sn(Ra)(Rb), C(Ra)(Rb) or P(=O)(Ra); Ra and Rb independently represent a hydrogen atom, an alkyl group or an aryl group; and Y represents a C1-C3 alkylene group).
5.WO/2020/235947CACB1-DERIVED PEPTIDE, VARIANT OF CACB1-DERIVED PEPTIDE, AND USE THEREOF
WO 26.11.2020
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No PCT/KR2020/006650 Applicant KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor YOUN, Dong-ho
The present invention relates to a Cacb1-derived peptide, a variant of the Cacb1-derived peptide, a composition for the prevention or treatment of hypertension, and a composition for the relaxation of blood vessels, the compositions comprising same. The Cacb1-derived peptide and the variant of the Cacb1-derived peptide according to the present invention have an excellent blood pressure-lowering effect and fewer side effects, and are easy to manufacture and industrialize, and thus can be effectively used in the development of a novel therapeutic agent for hypertension. In addition, the peptide and the variant thereof have a potential vasodilating effect, and thus are expected to be used as candidate materials for a therapeutic agent for diseases that can be treated or ameliorated by vasodilation, such as angina, prostatic hyperplasia, and erectile dysfunction.
6.WO/2020/236797VARIANT CD58 DOMAINS AND USES THEREOF
WO 26.11.2020
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/US2020/033566 Applicant NOVARTIS AG Inventor BRANNETTI, Barbara
The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.
7.WO/2020/236917METHODS FOR IMPROVING THE TISSUE SEALING PROPERTIES OF HYDROGELS AND THE USE THEREOF
WO 26.11.2020
Int.Class A61L 27/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
27Materials for prostheses or for coating prostheses
50Materials characterised by their function or physical properties
52Hydrogels or hydrocolloids
Appl.No PCT/US2020/033775 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor SHEIKHI, Amir
Naturally-derived biopolymers, such as proteins and polysaccharides are a promising platform for developing materials that readily adhere to tissues upon chemical crosslinking and provide a regenerative microenvironment. Here, we show that the sealing properties of a model biopoiymer sealant, gelatin methacryloyl (GelMA), can be precisely controlled by adding a small amount of a synthetic polymer with identically reactive moieties, i.e., poly (ethylene glycol) diacrylate (PEG DA). For example, we have discovered a more than 300% improvement in tissue sealing capability of 20% (w/v) GelMA adhesive can be obtained by adding only 2- 3% (v/v) PEGDA, without any significant effect on the sealant degradation time scale. These hybrid hydrogels with improved sealing properties are suitable for sealing stretchable organs, such as bladder, as well as for the anastomosis of tubular tissues/organs.
8.WO/2020/237227CIRCULAR RNA COMPOSITIONS AND METHODS
WO 26.11.2020
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2020/034418 Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY Inventor WESSELHOEFT, Alexander
Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
9.WO/2020/234556CONJUGATES
WO 26.11.2020
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/GB2020/050781 Applicant ELASMOGEN LTD Inventor BARELLE, Caroline Jane
The invention provides a specific antigen binding molecule-substrate conjugate, comprising: (a) a specific antigen binding molecule having an amino acid sequence represented by the formula FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which FW1, FW2, FW3a, FW3b, and FW4 are Framework Regions, CDR1 and CDR3 are Complementarity Determining Regions, and HV2, and HV4 are Hypervariable Regions; and (b) a substrate.
10.WO/2020/236146A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME
WO 26.11.2020
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/US2019/033046 Applicant THE TEXAS A&M UNIVERSITY SYSTEM Inventor LIU, Wenshe
Embodiments of the present disclosure pertain to methods of selecting cyclic peptides that bind to a target by transforming a phage display library with a plurality of nucleic acids into bacterial host cells, where the nucleic acids include phage coat protein genes with a combinatorial region that encodes at least one cysteine and at least one non-canonical amino acid. The transformation results in the production of phage particles with phage coat proteins where the cysteine and the non-canonical amino acid couple to one another to form a cyclic peptide library. Phage particles are then screened against the desired target to select bound cyclic peptides. Amino acid sequences of the selected cyclic peptides are then identified. Additional embodiments pertain to methods of constructing a phage display library that encodes the cyclic peptides. Further embodiments of the present disclosure pertain to the produced cyclic peptides, phage display libraries and phage particles.